These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 30361285)

  • 21. Preventing Cross-Contamination during Lyophilization: GMP and Occupational Cleaning Requirements for Nonproduct and Indirect Product-Contact Parts.
    Denk R; Flückiger A; Kisaka H; Krause S; Maeck R; Restetzki L; Schreiner A; Schulze R
    PDA J Pharm Sci Technol; 2019; 73(5):487-495. PubMed ID: 31420508
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regulatory and quality considerations for continuous manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium.
    Allison G; Cain YT; Cooney C; Garcia T; Bizjak TG; Holte O; Jagota N; Komas B; Korakianiti E; Kourti D; Madurawe R; Morefield E; Montgomery F; Nasr M; Randolph W; Robert JL; Rudd D; Zezza D
    J Pharm Sci; 2015 Mar; 104(3):803-12. PubMed ID: 25830179
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of Particulate Matter in Liquid-Finished Dosage Forms.
    Duchek J; Havasi B
    PDA J Pharm Sci Technol; 2018; 72(6):608-625. PubMed ID: 29853612
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Media-fill simulation tests in manual and robotic aseptic preparation of injection solutions in syringes.
    Krämer I; Federici M; Kaiser V; Thiesen J
    J Oncol Pharm Pract; 2016 Apr; 22(2):195-204. PubMed ID: 25549919
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monitoring minimization of grade B environments based on risk assessment using three-dimensional airflow measurements and computer simulation.
    Katayama H; Higo T; Tokunaga Y; Katoh S; Hiyama Y; Morikawa K
    PDA J Pharm Sci Technol; 2008; 62(4):244-55. PubMed ID: 19174953
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Microbiological in-process control in drug manufacture].
    Seyfarth VH
    Arzneimittelforschung; 1985; 35(1A):205-16. PubMed ID: 4039162
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Proposal for a new categorization of aseptic processing facilities based on risk assessment scores.
    Katayama H; Toda A; Tokunaga Y; Katoh S
    PDA J Pharm Sci Technol; 2008; 62(4):235-43. PubMed ID: 19174952
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [A centralized system of particle counting in controlled zones].
    Hervieux D
    Boll Chim Farm; 1991 Jun; 130(6):218-21. PubMed ID: 1756006
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The biotest RCS air samplers in unidirectional flow.
    Ljungqvist B; Reinmüller B
    J Pharm Sci Technol; 1994; 48(1):41-4. PubMed ID: 8004418
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A practical discussion of risk management for manufacturing of pharmaceutical products.
    Mollah AH; Baseman HS; Long M; Rathore AS
    PDA J Pharm Sci Technol; 2014; 68(3):271-80. PubMed ID: 25188348
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interaction between air movements and the dispersion of contaminants: clean zones with unidirectional air flow.
    Ljungqvist B; Reinmüller B
    J Parenter Sci Technol; 1993; 47(2):60-9. PubMed ID: 8515346
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Equipment and analytical companies meeting continuous challenges. May 20-21, 2014 Continuous Manufacturing Symposium.
    Page T; Dubina H; Fillipi G; Guidat R; Patnaik S; Poechlauer P; Shering P; Guinn M; Mcdonnell P; Johnston C
    J Pharm Sci; 2015 Mar; 104(3):821-31. PubMed ID: 25448273
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Environmental Monitoring in a Pharmaceutical Manufacturing Facility Using a Culture Independent Approach].
    Kawai M
    Yakugaku Zasshi; 2022; 142(1):33-37. PubMed ID: 34980749
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Opportunities and challenges of real-time release testing in biopharmaceutical manufacturing.
    Jiang M; Severson KA; Love JC; Madden H; Swann P; Zang L; Braatz RD
    Biotechnol Bioeng; 2017 Nov; 114(11):2445-2456. PubMed ID: 28710854
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Panel discussion: environmental sampling in an aseptic environment. I. Microbiological environmental monitoring.
    Raiman HL
    Bull Parenter Drug Assoc; 1974; 28(6):253-60. PubMed ID: 4616742
    [No Abstract]   [Full Text] [Related]  

  • 36. Risk-Based Selection of Environmental Classifications for Biopharmaceutical Operations.
    Bevan N; Corbidge T; Estape D; Hovmand Lyster L; Magnus J
    PDA J Pharm Sci Technol; 2021; 75(4):374-390. PubMed ID: 33443138
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Validation Studies for Microbial Contamination and Control of Contaminants.
    Shintani H
    Biocontrol Sci; 2015; 20(3):161-70. PubMed ID: 26412695
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regulatory Perspectives on Continuous Pharmaceutical Manufacturing: Moving From Theory to Practice: September 26-27, 2016, International Symposium on the Continuous Manufacturing of Pharmaceuticals.
    Nasr MM; Krumme M; Matsuda Y; Trout BL; Badman C; Mascia S; Cooney CL; Jensen KD; Florence A; Johnston C; Konstantinov K; Lee SL
    J Pharm Sci; 2017 Nov; 106(11):3199-3206. PubMed ID: 28655487
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Validation study on how to avoid microbial contamination during pharmaceutical production.
    Shintani H
    Biocontrol Sci; 2015; 20(1):1-10. PubMed ID: 25817807
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hazard analyses of airborne contamination in clean rooms--application of a method for limitation of risks.
    Ljungqvist B; Reinmüller B
    PDA J Pharm Sci Technol; 1995; 49(5):239-43. PubMed ID: 7489198
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.